EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Middle meningeal artery embolization for chronic subdural hematoma: meta-analysis of three randomized controlled trials and review of ongoing trials

Conor S Gillespie, Munashe Veremu, William H Cook, Mohammad Ashraf, Keng Siang Lee, Youssef Chedid, Ali M Alam, Yevgeny Karepov, Benjamin M Davies, Ellie Edlmann, Panagiotis Papanagiotou, Stefanos Korfias und 4 weitere

Acta Neurochirurgica · 10.06.2025 · 167 (1)

DOI: 10.1007/s00701-025-06587-4 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Acta Neurochirurgica, online erschienen am 10.06.2025. Verfasst von Conor S Gillespie und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK. cg823@cam.ac.uk. Hauptthemen laut MEDLINE: Hematoma, Subdural, Chronic, Embolization, Therapeutic, Meningeal Arteries. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Middle Meningeal Artery Embolization (MMAE) has been proposed as adjunct and stand-alone treatment for Chronic Subdural Hematoma (CSDH). We aimed to meta-analyze three recently published randomized controlled trials, to reliably estimate the effect of MMAE. We also carried out a systematic review of ongoing trials and their key outcomes.

Methods

A PRISMA-compliant meta-analysis was conducted (PROSPERO ID CRD42024618816). Three published RCTs (MAGIC-MT, EMBOLISE, and STEM) assessing MMAE in CSDH were included. Trial primary outcomes were pooled for analysis using random effects models. Primary and secondary outcomes (recurrence/surgical rescue, functional outcome) were obtained, stratified by treatment group (undergoing surgery, and nonsurgical management). A descriptive review of trials in public registries was also conducted (search date 30th November 2024).

Results

In total, 1432 patients were included from three trials in meta-analysis. Overall, MMAE reduced symptomatic progression or recurrence, but was not statistically significant (RR 0.50, 95% CI 0.23–1.06, P = 0.058). For the group undergoing surgery, MMAE was not associated with reduced recurrence (RR 0.60, 95% CI 0.19–1.88, P = 0.194). For nonsurgical management, MMAE reduced progression (RR 0.36, 95% CI 0.22–0.60, P < 0.001). MMAE did not influence functional outcome (RR 1.01, 95% CI 0.97–1.04, P = 0.790). From the literature search, there are twenty-one registered trials. Nineteen studies include arms assessing MMAE as an adjunct to surgery, eleven compare MMAE to observation, and four with surgery. The most common primary outcome is recurrence (47.8%, N = 11), either radiologically, or requiring a second surgery. Inclusion criteria, embolization agents, primary and secondary outcomes differed significantly between studies.

Conclusions

In this meta-analysis of three randomized controlled trials, the use of MMAE in patients undergoing surgery did not appear to significantly reduce recurrence or improve functional outcomes, but did reduce progression in nonsurgical cohorts. Further studies assessing these cohorts are ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematoma, Subdural, ChronicEmbolization, TherapeuticMeningeal ArteriesHumansRandomized Controlled Trials as TopicRecurrenceTreatment Outcome

Stichwörter der Autor:innen

Chronic subdural hematomaMMAEMiddle meningeal artery embolization

Autor:innen und Institutionen

  • Department of Clinical Neurosciences, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK. cg823@cam.ac.uk.
  • Department of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. cg823@cam.ac.uk.
  • Department of Clinical Neurosciences, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK.
  • Department of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Wolfson School of Medicine, University of Glasgow, Glasgow, Scotland, UK.
  • Department of Basic and Clinical Neurosciences, Maurice, Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience , King's College London, London, UK.

Zitieren

APA

Gillespie, C. S., Veremu, M., Cook, W. H., Ashraf, M., Lee, K. S., Chedid, Y., Alam, A. M., Karepov, Y., Davies, B. M., Edlmann, E., Papanagiotou, P., Korfias, S., Santarius, T., Minett, T., Hutchinson, P. J., & Kolias, A. (2025). Middle meningeal artery embolization for chronic subdural hematoma: meta-analysis of three randomized controlled trials and review of ongoing trials. Acta Neurochirurgica, 167(1). https://doi.org/10.1007/s00701-025-06587-4

Vancouver

Gillespie CS, Veremu M, Cook WH, Ashraf M, Lee KS, Chedid Y, et al. Middle meningeal artery embolization for chronic subdural hematoma: meta-analysis of three randomized controlled trials and review of ongoing trials. Acta Neurochirurgica. 2025;167(1). doi:10.1007/s00701-025-06587-4

BibTeX
@article{Gillespie2025,
  author = {Gillespie, Conor S and Veremu, Munashe and Cook, William H and Ashraf, Mohammad and Lee, Keng Siang and Chedid, Youssef and Alam, Ali M and Karepov, Yevgeny and Davies, Benjamin M and Edlmann, Ellie and Papanagiotou, Panagiotis and Korfias, Stefanos and Santarius, Thomas and Minett, Thais and Hutchinson, Peter J and Kolias, Angelos},
  title = {Middle meningeal artery embolization for chronic subdural hematoma: meta-analysis of three randomized controlled trials and review of ongoing trials},
  journal = {Acta Neurochirurgica},
  year = {2025},
  volume = {167},
  number = {1},
  doi = {10.1007/s00701-025-06587-4}
}
Kostenlos starten →